ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025

Rhea-AI Summary

ORIC Pharmaceuticals (Nasdaq: ORIC) announced two late-breaking oral presentations of Phase 1b data for enozertinib (ORIC-114) at the ESMO Asia Congress 2025 in Singapore (December 5–7, 2025).

The mini-oral (LBA15) on Dec 5, 2025 at 11:38–11:43 a.m. SGT covers previously treated EGFR atypical mutant NSCLC with randomized dose optimization and CNS activity. The proffered paper oral (LBA13) on Dec 6, 2025 at 10:02–10:12 a.m. SGT covers EGFR exon 20 mutant NSCLC in previously treated and treatment-naïve patients. ORIC will host a conference call and webcast on Dec 6, 2025 at 8:00 p.m. ET, with a replay available for 90 days.

Insights

Clinical Oncology Analyst

Late-breaking Phase 1b presentations highlight safety and activity data for enozertinib in EGFR atypical and exon 20 NSCLC at ESMO Asia.

ORIC presents randomized dose-optimization and CNS-activity data from a Phase 1b trial of enozertinib (ORIC-114) in two distinct EGFR-mutant cohorts, which advances the program through the clinical-readout and visibility channels that matter to regulators and clinicians.

The immediate value depends strictly on the disclosed data; absent explicit efficacy or safety outcomes here, the primary dependencies are the numeric safety/tolerability profile, CNS-penetration measures, and any reported response rates or duration metrics. Any unfavorable safety signals or weak activity would materially change interpretation.

Watch the mini-oral on December 5, 2025 (LBA15) and the proffered paper on December 6, 2025 (LBA13), plus the company webcast and Q&A on December 6, 2025 at 8:00 pm ET; the webcast replay will remain available for 90 days. Key items to extract from the presentations are objective response rate, intracranial response data, dose selected after randomized optimization, and safety/tolerability tables; those metrics will determine near-term clinical and regulatory relevance.

Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET

SOUTH SAN FRANCISCO and SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced two late-breaking oral presentations highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025 taking place December 5-7, 2025 in Singapore. The mini-oral presentation will focus on data in previously treated patients with EGFR atypical mutant NSCLC, and the proffered paper oral presentation will focus on data in previously treated and treatment-naïve patients with EGFR exon 20 mutant NCSLC.

Mini-oral presentation details:
Title:	Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant EGFR and HER2 Inhibitor, in Previously Treated NSCLC with EGFR Atypical Mutations: Randomized Dose Optimization and CNS Activity
Presentation Number:	LBA15
Session Type and Title:	Mini Oral session 1: Thoracic malignancies
Lecture Date and Time:	Friday, December 5, 2025; 11:38 – 11:43 a.m. SGT

Proffered paper oral presentation details:
Title:	Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant EGFR and HER2 Inhibitor, in EGFR Exon 20 Mutant NSCLC: Randomized Dose Optimization and CNS Activity
Presentation Number:	LBA13
Session Type and Title:	Proffered Paper session: Thoracic malignancies
Lecture Date and Time:	Saturday, December 6, 2025; 10:02 – 10:12 a.m. SGT

Full late-breaking abstracts are available for public viewing via the ESMO Asia Congress website.

Conference Call and Webcast Details
In conjunction with the ESMO Asia Congress, ORIC will host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. A live webcast and audio archive of the conference call will be available through the investor section of ORIC’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.

About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib (ORIC-114), a brain-penetrant inhibitor that selectively targets EGFR exon 20, EGFR atypical, and HER2 exon 20 mutations, being developed across multiple genetically defined cancers. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Contact:

Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

FAQ

When will ORIC present enozertinib (ORIC-114) data at ESMO Asia 2025?

Two presentations: mini-oral LBA15 on Dec 5, 2025, 11:38–11:43 a.m. SGT and proffered paper LBA13 on Dec 6, 2025, 10:02–10:12 a.m. SGT.

What patient groups are covered in the ORIC enozertinib ESMO Asia presentations?

The mini-oral focuses on previously treated EGFR atypical mutant NSCLC; the proffered paper covers previously treated and treatment‑naïve EGFR exon 20 mutant NSCLC.

How can investors access ORIC's conference call and webcast on Dec 6, 2025?

ORIC will host a conference call and live webcast on Dec 6, 2025 at 8:00 p.m. ET; pre-registration is required for phone access and the webcast replay will be on ORIC's investor website for 90 days.

What topics do the enozertinib ESMO abstracts emphasize?

Both abstracts highlight randomized dose optimization and CNS activity of enozertinib in EGFR/HER2‑driven NSCLC populations.

Where can I find the full late‑breaking abstracts for ORIC's enozertinib presentations?

Full late‑breaking abstracts are available for public viewing on the ESMO Asia Congress 2025 website.

Which ORIC presentation at ESMO Asia 2025 is labeled LBA13 and what is its focus?

Presentation LBA13 is the proffered paper oral on Dec 6, 2025, focusing on enozertinib in EGFR exon 20 mutant NSCLC including previously treated and treatment‑naïve patients.